This company has been acquired
Salud financiera de hoja de balance de Provention Bio
Salud financiera controles de criterios 5/6
Provention Bio has a total shareholder equity of $121.8M and total debt of $23.5M, which brings its debt-to-equity ratio to 19.3%. Its total assets and total liabilities are $236.9M and $115.0M respectively.
Información clave
19.3%
Ratio deuda-patrimonio
US$23.47m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$165.00m |
| Patrimonio | US$121.85m |
| Total pasivo | US$115.01m |
| Activos totales | US$236.86m |
Actualizaciones recientes sobre salud financiera
Is Provention Bio (NASDAQ:PRVB) In A Good Position To Invest In Growth?
Jan 11
Is Provention Bio (NASDAQ:PRVB) In A Good Position To Deliver On Growth Plans?
Aug 26Provention Bio (NASDAQ:PRVB) Is In A Good Position To Deliver On Growth Plans
Jan 06Recent updates
Provention Bio appoints O'Brien as Chief People Officer
Sep 19Provention Bio secures $125M term loan facility
Sep 01Provention Bio: More Risk, More Dilution Ahead - Downgrading To A Sell Rating
Aug 12Provention Bio Q2 2022 Earnings Preview
Aug 03Provention Bio to raise $60M through private placement of securities
Jul 08Provention Bio says FDA extends review period for co's teplizumab application to Nov. 17
Jun 30Provention Bio (PRVB): BLA Accepted; Downgrading To A Hold
Mar 31Provention Bio: Upgrading To A Strong-Buy, Potential Cure For Type 1 Diabetes
Feb 04Is Provention Bio (NASDAQ:PRVB) In A Good Position To Invest In Growth?
Jan 11Is Provention Bio (NASDAQ:PRVB) In A Good Position To Deliver On Growth Plans?
Aug 26Provention Bio: Blood (Glucose) In The Streets
Jul 30FDA Advisory Committee supports Provention Bio's teplizumab in delaying diabetes
May 28Provention Bio EPS misses by $0.05
May 06Provention Bio provides regulatory update on teplizumab BLA
Apr 27How Much Of Provention Bio, Inc. (NASDAQ:PRVB) Do Insiders Own?
Mar 17Need To Know: Provention Bio, Inc. (NASDAQ:PRVB) Insiders Have Been Buying Shares
Feb 10
Provention Bio prices $100M stock offering
Jan 14Provention Bio Could See Meaningful Upside Once Teplizumab Hits The Market
Jan 07Provention Bio (NASDAQ:PRVB) Is In A Good Position To Deliver On Growth Plans
Jan 06Provention Bio files US application for its diabetes drug
Jan 04Provention Bio launches first-in-human PRV-101 study in coxsackievirus B
Dec 15Is Provention Bio, Inc.'s (NASDAQ:PRVB) Shareholder Ownership Skewed Towards Insiders?
Dec 02Provention Bio EPS misses by $0.14
Nov 05Análisis de la situación financiera
Pasivos a corto plazo: PRVB's short term assets ($174.6M) exceed its short term liabilities ($90.4M).
Pasivo a largo plazo: PRVB's short term assets ($174.6M) exceed its long term liabilities ($24.6M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: PRVB has more cash than its total debt.
Reducción de la deuda: PRVB's debt to equity ratio has increased from 0% to 19.3% over the past 5 years.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: PRVB has sufficient cash runway for more than a year based on its current free cash flow.
Pronóstico de cash runway: PRVB is forecast to have sufficient cash runway for 10 months based on free cash flow estimates, but has since raised additional capital.